ClinicalTrials.gg
RecruitingNCT06575530Updated Jun 16, 2026

Efficacy and Safety of Remimazolam Besylate for Sedation in Post-Non-Cardiac Surgery Patients Requiring Mechanical Ventilation

A Phase 4 interventional study of Remimazolam Besylate and Dexmedetomidine Hydrochloride in Effect of Drug, Adverse Drug Event and Mechanical Ventilation Complication, sponsored by Beijing Shijitan Hospital, Capital Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Beijing Shijitan Hospital, Capital Medical University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China — 14 open to participants now, 15 under way, none of them phase 3. Drug-Related Side Effects and Adverse Reactions · China.

Planned enrollment
2nd of 33
306 · median 44
Started
2025
with 4 others
Phase 4
3 of 53
1 open now
Primary completion
2026-05
later than 7 of 14 live
Registered
46th of 53
by date

Among the 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China, this one is the 2nd largest by planned enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 4, reaches primary completion later than 7 of the 14 other live ones, and was the 46th registered.

Drug-Related Side Effects and Adverse Reactions

449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.

Browse Drug-Related Side Effects and Adverse Reactions studies →

Open to participants now

14 of the 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 38 (68%) set no upper age limit and 15 (27%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China, or all of them as a file.
02

Study summary

A multi-center, prospective, randomized, double-blind, active-controlled, no-inferiority clinical trial conducted across 5 tertiary medical centers in China. The objective of this RCT is to evaluate the sedative efficacy and safety profile of remimazolam besylate compared with dexmedetomidine in patients requiring mechanical ventilation following non-cardiac surgery. The study hypothesized that remimazolam besylate is non-inferior to dexmedetomidine regarding the primary efficacy outcome.

03

Conditions studied

  • Effect of Drug
  • Adverse Drug Event
  • Mechanical Ventilation Complication
  • Critical Illness
  • Surgery
  • Sedation
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 64 years
  • Scheduled to undergo elective non-cardiac surgery
  • Planned for general anesthesia
  • With or without combined regional nerve blockade
  • Admitted to the ICU with endotracheal intubation post-surgery
  • With an anticipated duration of postoperative mechanical ventilation greater than 24 hours
  • Clinically requiring light sedation( target RASS score 0 to -2)

Exclusion criteria

Exclusion Criteria:

  • Undergoing intracranial surgery, or having a history of severe neurological or spinal cord diseases
  • Pre-existing history of schizophrenia, epilepsy, or Parkinson's disease
  • Inability to communicate preoperatively due to coma, severe dementia, or language barriers
  • Preoperative .cardiac insufficiency or severe cardiac arrhythmias
  • Severe hepatic impariment( class C)
  • Severe renal impariment
  • Preoperative( within 24 hours prior to surgery) or intraoperative administration of dexmedetomidine or remimazolam
  • Pregnancy or lactation
  • Participation in any clinical trial involving drugs within 30 days prior to enrollment
  • Any other conditions deemed by the investigators to render the patient unsuitable for study participation
  • Refusal to provide written
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
306 participants (estimated)

Study arms

  • Experimental
    remimazolam besylate group

    Upon ICU admission, remimazolam besylate infusion will initiated for light sedation maintenance at a dose range of 0.1 to1.0mg/Kg/h. The target sedation depth is defined as a RASS score of 0 to -2. The RASS score will evaluated and recorded hourly, and the infusion rate of remimazolam besylate will titrated( increased or decreased) accordingly to maintain the patient within the target sedation range. For multimodal analgesia, remifentanil will co-administered continuously at a dose of 0.1 to 0.5ug/Kg/min to ensure a CPOT score of 2 or less.

    Drug: Remimazolam Besylate

  • Active comparator
    Dexmedetomidine hydrochloride group

    Upon ICU admission, dexmedetomidine infusion will initiated for light sedation maintenance at a dose range of 0.2 to0.7ug/Kg/h. The target sedation depth is defined as a RASS score of 0 to -2. The RASS score will evaluated and recorded hourly, and the infusion rate of dexmedetomidine will titrated( increased or decreased) accordingly to maintain the patient within the target sedation range. For multimodal analgesia, remifentanil will co-administered continuously at a dose of 0.1 to 0.5ug/Kg/min to ensure a CPOT score of 2 or less.

    Drug: Dexmedetomidine Hydrochloride

Interventions

  • DrugRemimazolam besilateStudies of Remimazolam besilateRemimazolam besilate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    patients will be sedated with remimazolam via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. If the target sedation depth could not to achieved within the prespecified maximum dose range of remimazolam, a standardized rescue sedation protocol will intiated as follows: an intravenous bolus of propofol at 0.2mg/kg will administered. Sedation depth will evaluated 5 minutes post-injection. The identical dose of propofol bolus will repeated until the desired sedation depth is reached. Continuous propofol infusion will initiated after three consecutive bolus injections of propofol. The continuous propofol infusion rate will titrated within the range of 0.2 to 1.0 mg/kg/h until the satisfactory target sedation depth is established. At the subsequent hourly sedation assessment, continuous propofol infusion will discontinued once the patient successfully maintained a stable RASS score within the 0 to -2 range.

  • DrugDexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    patients will be sedated with dexmedetomidine hydrochloride via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. If the target sedation depth could not to achieved within the prespecified maximum dose range of remimazolam, a standardized rescue sedation protocol will intiated as follows: an intravenous bolus of propofol at 0.2mg/kg will administered. Sedation depth will evaluated 5 minutes post-injection. The identical dose of propofol bolus will repeated until the desired sedation depth is reached. Continuous propofol infusion will initiated after three consecutive bolus injections. The continuous propofol infusion rate will titrated within the range of 0.2 to 1.0 mg/kg/h until the satisfactory target sedation depth is established. At the subsequent hourly sedation assessment, continuous propofol infusion will discontinued once the patient successfully maintained a stable RASS score within the 0 to -2 range.

06

What researchers measure

Primary outcomes

  1. Percentage of time in optimal sedation

    Percentage of time in optimal sedation during sedation in the ICU, sedation depth is assessed using Richmond Agitation Sedation Scale(RASS, -5 to +4), target sedation must has a RASS score -2 to 0.

    Time frame: Through the useage of sedative drugs in the ICU, an average of 3 days

Secondary outcomes

  1. Ventilation free days

    Ventilation free days(VFDs) at 28 days. VFDs=0 if subject dies within 28 days of mechaincal ventilation; VFDs=28-X if successfully liberated from ventilation X days after initiation,if the patient is reintubated within 28 days, "X" represents the days of the last extubation; VFDs=0 if the subject is mechaincally ventilated for \>28 days.

    Time frame: Through the initiation of enrollment to 28 days, an average of 1 day

  2. Dosage of rescue sedatives

    Dosage of rescue sedatives during mechanical ventilation in the ICU

    Time frame: Through the useage of sedative drugs in the ICU, an average of 3 days

  3. Frequency of rescue sedatives

    Frequency of rescue sedatives during mechanical ventilation in the ICU

    Time frame: Through the useage of sedative drugs in the ICU, an average of 3 days

  4. Delirium incidence

    Delirium incidence during the patients' ICU stay, assessed using ConfusionAssessmentMethodfortheIntensive CareUnit(CAM-ICU, 4 items), delirium is diagnosed when 3 items are met

    Time frame: Through the ICU stay, an average of 3 days

  5. post-sedation extubation time

    Extubation time(hour) after termination of sedation

    Time frame: From ICU admission to extubation, an average of 3 days

  6. Re-mechanical ventilation incidence after weaning and extubation

    Re-mechanical ventilation incidence after weaning and extubation

    Time frame: Through the ICU stay, an average of 3 days

  7. Proportion of different oxygen therapies post-extubation

    Proportion of different oxygen therapies post-extubation

    Time frame: Through the ICU stay, an average of 3 days

  8. Pain scores during the first 3 postoperative days

    Pain scores during the first 3 postoperative days, assessed using Critical-Care Pain Observation Tool(CPOT,0-8), the higher the score, the more painful the patient feels

    Time frame: The first 3 days of ICU stay, an average of 3 days

  9. Sleep quality scores on the day of ICU discharge

    Sleep quality scores on the day of ICU discharge, assessed using St.Mary'sHospitalSleepQuestionnaire(SMHSQ, 11 to 55), the lower the score, the higher the degree of sleep disorders

    Time frame: The day transfer out of ICU, an average of 1day

  10. Cognitive assessment scores on postoperative day 60

    Cognitive assessment scores on postoperative day 60, assessed using Telephone Interview for Cognitive Status-Modified(TICS-m,0-50), the higher the score, the better the cognitive function

    Time frame: Day 60 after surgery, an average of 1 day

  11. Sleep quality scores on postoperative day 60

    Sleep quality scores on postoperative day 60 assessed using Pittsburgh sleep quality index(PSQI,0-21), the higher the score, the worse the sleep quality

    Time frame: Day 60 after surgery, an average of 1 day

  12. ICU LOS

    ICU length of stay

    Time frame: The day the patient transfer out of ICU, an average of 1 day

  13. Postoperative hospital LOS

    postoperative hospital length of stay

    Time frame: The day the patient discharge, an average of 1 day

  14. 60-day all-cause mortality

    60-day all-cause mortality

    Time frame: Day 60 postoperative, an average of 1 day

  15. 60-day non-neurological complications

    60-day non-neurological complications

    Time frame: Day 60 postoperative, an average of 1 day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in May 2026, 16 months.

Of 18 phase 4 interventional studies under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 37. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2024
First posted
Aug 28, 2024
StartActual
Jan 20, 2025
Primary completionActual
May 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06575530
Lead sponsor
Beijing Shijitan Hospital, Capital Medical University
Responsible party
Sponsor
First posted
Aug 28, 2024
Start date
Jan 20, 2025
Primary completion
May 30, 2026
Completion
Jun 30, 2026 (estimated)
Last update
Jun 16, 2026

Study contacts

Yuefu Wang, doctor
Contact
wangyuefu3806@bjsjth.cn
+86 ext. 15301306289
Dandan Liu, doctor
Contact
ldd3967@163.com
+86 ext. 13810589291
Jianxin Zhou, doctor
study chair · Beijing Shijitan Hospital, Capital Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam besilate

Start the discussion